In the BehandelStrategieën (BeSt) study, 508 patients with recent onset RA were randomised to four treatment strategies aimed at a DAS ≤2.4. Risks of damage progression and (drug-free) remission in 8 years were compared for ACPA-positive and ACPA-negative patients, using logistic regression analysis. Functional ability and DAS components over time were compared using linear mixed models.
INTRODUCTION
Anticitrullinated protein antibodies (ACPAs) are highly specific antibodies for rheumatoid arthritis.(RA) [1] Patients positive for ACPA have been shown to have higher disease activity, [2, 3] worse functional ability [4, 5] and more joint damage [2, 3, 6 ,7] in observational and/or non-disease activity-steered studies. ACPA-positivity was found to be predictive of not achieving remission.
[8] ACPA-negative and ACPA-positive RA may be different diseases with different risk factors and clinical course and may require different therapeutic strategies.[9,10,11] Possibly ACPA-positive and ACPA-negative patients also respond differently in a tight control treatment strategy where medication is adjusted based on the aim of achieving low disease activity. Therefore, we compared the changes in Disease Activity Score (DAS) functional ability and radiological damage over time in ACPA-positive and ACPA-negative patients with early RA treated according to the same disease activity steered protocol.
METHODS

Patients
Eight-year follow-up data of all 484 patients with known ACPA-status included in the BeSt (Dutch acronym for BehandelStrategieën, "treatment strategies") study were analyzed. This is a multi-centre randomised trial designed to compare four treatment strategies in 508 patients with recent-onset RA; initial monotherapy, step-up combination therapy (both starting with methotrexate monotherapy for ≥6 months), initial combination therapy with methotrexate, sulfasalazine and prednisolone and initial combination therapy with methotrexate and infliximab. Treatment was assessed every 3 months and adjusted if the DAS was >2.4. If the DAS was ≤2.4 for ≥6 months, medication was tapered to monotherapy in maintenance dose. Starting 2 years after inclusion, patients on monotherapy maintenance dose, who were in remission (DAS <1.6) for ≥6 months, stopped the last disease modifying antirheumatic drug (DMARD). Treatment was restarted if the DAS increased to ≥1.6. A more detailed description of the study protocol was published previously.
[12]
Study endpoints
ACPA-status was determined with the CCP2 test using baseline sera (n=119) and sera collected during the first years of follow-up (n=365). The DAS and Health Assessment Questionnaire (HAQ) were used to assess treatment response. Drug-free remission was defined as a DAS <1.6 and not using any DMARD. All available x-rays of hands and feet at year 0-1-2-3-4-5-6-7-8 were scored using the Sharp/van der Heijde score (SHS) by two independent readers, blinded for patient identity and time order (inter-observer intraclass correlation coefficient 0.96), to assess joint damage. For DAS and DAS components, areas under the curve (AUC) were calculated, only for years with complete data. For years with ≤2 missing values, the last observation carried forward was used to calculate the AUC,to avoid exclusion of these data.
Statistical analysis
Baseline characteristics and clinical parameters were compared using the χ 2 test, Student t test or Mann-Whitney U test. HAQ and DAS components over time were compared using linear mixed models with ACPA-status and time as categorical variables and HAQ or DAS component respectively at baseline, adjusted for baseline gender, smoking habits, age and SHS with a Toeplitz covariance structure. Spearman's correlation coefficient test was used to analyse the correlations after 8 years. ORs for achieving (drug-free) remission, of restarting medication and of joint damage progression were calculated for ACPA-positive patients using logistic regression analyses, adjusted for gender, smoking habits, baseline age, DAS and SHS. ORs were converted to RRs to find a more accurate estimation of the effect size. [13] To examine the influence of treatment strategy, we used generalized estimating equations with an auto-regressive covariance structure, time as categorical variable, baseline SHS, DAS, age, gender, smoking habits, ACPA-status, treatment strategy and ACPA*treatment strategy with yearly damage progression as outcome. To assess the possible difference in the association between disease activity and joint damage progression for ACPA-positive and -negative patients, we used generalized estimating equations with these components but with treatment strategy replaced by yearly AUC
DAS or AUC DAS component (with baseline DAS component instead of baseline DAS).
RESULTS
Treatment response
ACPA-positive patients had a lower baseline DAS and HAQ and a higher SHS. Disease activity over time was similar in both ACPA-groups (figure 1a). Functional ability was not different for ACPA-positive and ACPA-negative patients (p=0.9) (figure 1b). This similar treatment response in both ACPA-groups was seen both in patients initially treated with methotrexate monotherapy and with combination therapy (p=0.8 and p=0.9) (supplemental file online 1). ACPA-positive patients did have a significantly higher and ACPA-negative patients after correction for disease activity and RF, but ACPApositive patients had more joint damage, which is in line with our results. The relatively short follow-up period may account for these findings, as radiological joint damage shows a weak correlation with functional ability in the first years after the diagnosis of RA, but a moderate correlation after 12 years, while disease activity shows a stable, moderate correlation with functional ability from baseline onwards. [14] In our tight controlled cohort we found a moderate correlation between functional ability and disease activity but no significant correlation with radiological joint damage after 8 years. Longer follow-up will show whether radiological joint damage will significantly contribute to functional disability with longer disease duration.
Our observation that ACPA-positivity is a predictor for not achieving drug-free remission and for relapsing if drug-free remission was achieved, is an extension on similar results after 5 years of treatment. [15] The results are also in line with the findings of Balsa et al, [5] who found that ACPA-positivity was a predictor for not achieving drug-free remission for ≥5 years, and of van der Woude et al [16] who found that ACPA-positivity was a predictor for not achieving drug-free remission for ≥1 year. It might be wise to take ACPA-status into consideration when contemplating cessation of medication.
In conclusion, DAS-steered therapy is equally effective in reducing disease activity, achieving remission and improving functional ability in ACPA-positive and ACPAnegative patients with recent-onset RA. Still, ACPA-positive patients had more radiological damage, especially patients initially treated with methotrexate monotherapy.
This suggests that in ACPA-positive patients, initial methotrexate monotherapy is insufficient to suppress joint damage progression even if subsequent treatment is DASsteered. This is in line with our previous findings [17, 18] Step 
